Physician profile
Keith Oliver Schluterman
NPI 1053318147
$66,747.20
in general payments reported to CMS, 2019-2025
66 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,186 · 2020: $3,413 · 2021: $27K · 2022: $10K · 2023: $4,924 · 2024: $5,984 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,377 · Consulting Fee: $1,525 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,259.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,376.98 |
| Consulting Fee | $1,525.00 |
| Education | $103.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $23,115.30 | 2020-2021 | |
| Pfizer INC. | $5,936.60 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $5,926.11 | 2022 | |
| Acorda Therapeutics, INC | $2,913.38 | 2019 | |
| Biogen, INC. | $2,012.10 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Jazz Pharmaceuticals INC. | $1,797.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,672.78 | 2019-2025 | |
| Amgen INC. | $1,524.97 | 2019-2025 | Uplizna, Aimovig |
| Abbvie INC. | $1,509.50 | 2019-2025 | Qulipta, Ubrelvy, Duopa |
| Emd Serono, INC. | $1,356.49 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $1,341.26 | 2019-2025 | Zilbrysq, Rystiggo, Briviact |
| Sk Life Science, INC. | $1,325.54 | 2020-2025 | |
| Lundbeck LLC | $1,251.70 | 2020-2025 | Vyepti, Rexulti |
| Mdd US Operations, LLC | $1,223.57 | 2019-2025 | Gocovri, Myobloc, Apokyn |
| Amneal Pharmaceuticals LLC | $1,120.32 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $956.04 | 2019-2025 | Nourianz |
| Neurocrine Biosciences, INC. | $924.24 | 2022-2025 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $775.25 | 2019-2024 | |
| Csl Behring | $735.56 | 2019-2025 | Hizentra |
| Genzyme Corporation | $732.56 | 2019-2025 | |
| Eisai INC. | $713.29 | 2020-2025 | |
| Lilly USA, LLC | $708.23 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Alexion Pharmaceuticals, INC. | $587.84 | 2019-2025 | Ultomiris |
| Upsher-Smith Laboratories LLC | $580.96 | 2019-2023 | |
| Inspire Medical Systems, INC. | $573.14 | 2021-2025 | Inspire |
| Acadia Pharmaceuticals INC | $568.87 | 2019-2025 | Nuplazid |
| Harmony Biosciences LLC | $498.63 | 2020-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $422.17 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Tg Therapeutics, INC. | $351.98 | 2023-2025 | |
| Allergan, INC. | $292.14 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $265.85 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Argenx US, INC. | $258.63 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Celgene Corporation | $251.02 | 2021-2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $208.15 | 2020-2024 | Acthar |
| Neurelis, INC. | $190.98 | 2021-2025 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $168.96 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $139.77 | 2019-2024 | Onpattro |
| Astrazeneca Pharmaceuticals Lp | $138.65 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $137.28 | 2022 | |
| Impel Pharmaceuticals INC. | $133.29 | 2023 | Trudhesa |
| Livanova USA, INC. | $130.31 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Axsome Therapeutics, INC. | $126.11 | 2023-2025 | Sunosi |
| Tanabe Pharma America, INC. | $117.42 | 2022-2024 | |
| Grifols USA, LLC | $116.63 | 2019-2025 | Gamunex-C |
| Nevro Corp. | $99.36 | 2022-2024 | Senza |
| Otsuka America Pharmaceutical, INC. | $98.54 | 2025 | Rexulti |
| Banner Life Sciences, LLC | $78.69 | 2022-2023 | |
| Genentech USA, INC. | $77.99 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Adamas Pharmaceuticals, INC. | $68.10 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $65.01 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $58.39 | 2019-2020 | |
| Zoll Respicardia, INC. | $57.36 | 2023 | Remede System |
| Catalyst Pharmaceuticals, INC. | $48.28 | 2023-2024 | Fycompa |
| Avadel Cns Pharmaceuticals, LLC | $46.98 | 2024 | Lumryz |
| Ipsen Biopharmaceuticals, INC | $32.41 | 2024 | Dysport |
| Avion Pharmaceuticals | $30.67 | 2022 | |
| Averitas Pharma INC. | $23.99 | 2024 | Qutenza |
| Abbott Laboratories | $16.47 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.12 | 2024 | Dojolvi |
| Elutia, INC. | $15.57 | 2020 | |
| Resmed Corp | $14.63 | 2022 | |
| Ge Healthcare | $14.27 | 2022 | |
| Merck Sharp & Dohme LLC | $14.19 | 2020 | |
| Globus Medical, INC. | $14.10 | 2025 | Omnia |
| Idorsia Pharmaceuticals US INC | $13.34 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Schluterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.